Jules Haimovitz Net Worth

Jules Haimovitz biography

Jules Haimovitz is an Independent Director of the Company. Mr. Haimovitz is currently President of Haimovitz Consulting, Inc. He previously served as a member of the board of directors of Ariad Pharmaceuticals, where he was also a member of the audit committee; Dial Global, Inc., where he was also member of the audit committee; and Imclone Pharmaceuticals, where he served as chairperson of the audit committee. Mr. Haimovitz has also served as Chief Executive Officer or Chief Operating Officer of the following companies: Spelling Entertainment, Inc., King World Productions and VJN, Inc. Mr. Haimovitz holds a B.S. and M.A. degree in Mathematics from Brooklyn College. Mr. Haimovitz has demonstrated leadership in his field, his knowledge of financial and financing matters and his prior board service contributed to our conclusion that he should serve as a director.

What is the salary of Jules Haimovitz?

As the Independent Director of Innoviva, the total compensation of Jules Haimovitz at Innoviva is $453,828. There are 1 executives at Innoviva getting paid more, with Marianne Zhen having the highest compensation of $477,405.

How old is Jules Haimovitz?

Jules Haimovitz is 68, he’s been the Independent Director of Innoviva since 2018. There are no older and 6 younger executives at Innoviva.

What’s Jules Haimovitz’s mailing address?

Jules’s mailing address filed with the SEC is 10900 NE 8TH STREET, SUITE 800, , BELLEVUE, WA, 98004.

Insider trading at Innoviva

Over the last 4 years, insiders at Innoviva have traded over $1,803,093 worth of Innoviva stock and bought 32,000 units worth $491,100 . The most active insider traders include James L Tyree, Patrick G Lepore, and Barbara Gayle Duncan. On average, Innoviva executives and independent directors trade stock every 42 days with the average trade being worth of $82,142. The most recent stock trade was executed by George Bickerstaff on 27 February 2019, trading 15,000 units of INVA stock currently worth $238,500.

What does Innoviva do?

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Innoviva executives and stock owners

Innoviva executives and other stock owners filed with the SEC include:

• Marianne Zhen, Chief Accounting Officer
• Jules Haimovitz, Independent Director
• Sarah Schlesinger, Independent Director
• Mark DiPaolo, Independent Director
• Odysseas Kostas, Independent Director
• Geoffrey Hulme, Interim Principal Executive Officer
• George Bickerstaff, Independent Director
• Paul Pepe, Director
• Michael W Aguiar, President & Chief Exec Officer
• Barbara Gayle Duncan, Director
• William H Waltrip, Director
• Theodore L Jr Witek, Sr. VP & Chief Scientific Off.
• Cathy Friedman, Director
• James L Tyree, Director
• Michael E. Faerm, Sr VP & Chief Business Officer
• George B Abercrombie, Sr. VP & Chief Comm. Officer
• Patrick G Lepore, Director
• Eric D Esparbes, SVP and CFO